June 24 (Reuters) - An advisory panel to the U.S. Food and
Drug Administration will be asked to vote next week on whether a
diabetes drug made by Eli Lilly & Co and Boehringer
Ingelheim cuts the risk of cardiovascular death, according to
documents posted on the agency's website on Friday.
Read more
No comments:
Post a Comment